The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Nat Biotechnol. 2019 Aug;37(8):869-876. doi: 10.1038/s41587-019-0171-6. Epub 2019 Jul 8.
Engineering the synthesis of massive amounts of therapeutics, enzymes or commodity chemicals can select for subpopulations of nonproducer cells, owing to metabolic burden and product toxicity. Deep DNA sequencing can be used to detect undesirable genetic heterogeneity in producer populations and diagnose associated genetic error modes. Hotspots of genetic heterogeneity can pinpoint mechanisms that underlie load problems and product toxicity. Understanding genetic heterogeneity will inform metabolic engineering and synthetic biology strategies to minimize the emergence of nonproducer mutants in scaled-up fermentations and maximize product quality and yield.
工程合成大量的治疗药物、酶或大宗商品化学品可能会因代谢负担和产品毒性而选择非生产细胞的亚群。深度 DNA 测序可用于检测生产群体中不理想的遗传异质性,并诊断相关的遗传错误模式。遗传异质性的热点可以确定导致负荷问题和产品毒性的机制。了解遗传异质性将为代谢工程和合成生物学策略提供信息,以最大限度地减少放大发酵中非生产突变体的出现,并最大限度地提高产品质量和产量。